Drug-induced Hyperbilirubinemia and the Clinical Influencing Factors

REFERENCES

• H. Ahn, C. S. Li, and W. Wang. (2005). Sickle cell hepatopathy: clinical presentation, treatment, and outcome in pediatric and adult patients. Pediatr. Blood Cancer 45:184–190.
   PubMed Web of Science ®Google Scholar
• K. Akaba, T. Kimura, A. Sasaki, S. Tanabe, T. Ikegami, M. Hashimoto, H. Umeda, H. Yoshida, K. Umetsu, H. Chiba, I. Yuasa, and K. Hayasaka. (1998). Neonatal hyperbilirubinemia and mutation of bilirubin UDP-glucuronosyltransferase gene: a common missense mutation among Japanese, Koreans and Chinese. Biochem. Mol. Biol. Int. 46:21–26.
   PubMedGoogle Scholar
• I. M. Arias, and I. M. London. (1957). Bilirubin glucuronide formation in vitro; demonstration of a defect in Gilbert's disease. Science 126:563–564.
   PubMed Web of Science ®Google Scholar
• Z. Arinzon, P. Alexander, and Y. Berner. (2004). Hydrochlorothiazide induced hepato-cholestatic liver injury. Age Ageing 33:509–510.
   PubMed Web of Science ®Google Scholar
• A. Berardi, L. Lugli, F. Ferrari, G. Gargano, M. D'Apolito, A. Marrone, and A. Iolascon. (2006). Kernicterus associated with hereditary spherocytosis and UGT1A1 promoter polymorphism. Biol. Neonate 90:243–246.
   PubMedGoogle Scholar
• P. D. Berk, and C. M. Noyer. (1994). The familial unconjugated hyperbilirubinemias. Semin. Liver Dis. 14:356–385.
   PubMed Web of Science ®Google Scholar
• S. S. Bhardwaj, and N. Chalasani. (2007). Lipid-lowering agents that cause drug-induced hepatotoxicity. Clin. Liver Dis. 11:597–613.
   PubMedGoogle Scholar
• C. L. Bickford, and A. P. Spencer. (2005). Biliary sludge and hyperbilirubinemia associated with ceftriaxone in an adult: case report and review of the literature. Pharmacotherapy 25:1389–1395.
   PubMed Web of Science ®Google Scholar
• M. Black, and B. H. Billing. (1969). Hepatic bilirubin UDP-glucuronyltransferase activity in liver disease and Gilbert's suyndrome. N. Engl. J. Med. 280:1266–1271.
   PubMed Web of Science ®Google Scholar
• H. L. Bonkovsky, R. Azar, S. Bird, G. Szabo, and B. Banner. (2002). Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone. Dig. Dis. Sci. 47:1632–1637.
   PubMed Web of Science ®Google Scholar
• T. M. Bosch, I. Meijerman, J. H. Beijnen, and J. H. Schellens. (2006). Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer. Clin. Pharmacokinet. 45:253–285.
   PubMed Web of Science ®Google Scholar
• P. J. Bosma, J. R. Chowdhury, C. Bakker, S. Gantla, A. de Boer, B. A. Oostra, D. Lindhout, G. N. Tytgat, P. L. Jansen, R. P. Oude Elferink, and N. R. Chowdhury. (1995). The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N. Engl. J. Med. 333:1171–1175.
   PubMed Web of Science ®Google Scholar
• M. A. Boyd, P. Srasuebkul, K. Ruxrungtham, P. I. Mackenzie, V. Uchaipichat, M. StekJr., J. M. Lange, P. Phanuphak, D. A. Cooper, W. Udomuksorn, and J. O. Miners. (2006). Relationship between hyperbilirubinaemia and UDP-glucuronosyltransferase 1A1 (UGT1A1) polymorphism in adult HIV-infected Thai patients treated with indinavir. Pharmacogenet. Genomics. 16:321–329.
   PubMed Web of Science ®Google Scholar
• B. Burchell. (2003). Genetic variation of human UDP-glucuronosyltransgerase: implications in disease and drug glucuronidation. Am. J. Pharmacogenomics 3:37–52.
   PubMedGoogle Scholar
• S. D. Campbell, S. M. de Morais, and J. J. Xu. (2004). Inhibition of human organic anion transporting polypeptide OATP 1B1 as a mechanism of drug-induced hyperbilirubinemia. Chem. Biol. Interact. 150:179–187.
   PubMed Web of Science ®Google Scholar
• D. Cebecauerova, T. Jirasek, L. Budisova, V. Mandys, V. Volf, Z. Novotna, I. Subhanova, M. Hrebicek, M. Elleder, and M. Jirsa. (2005). Dual hereditary jaundice: simultaneous occurrence of mutations causing Gilbert's and Dubin-Johnson syndrome. Gastroenterology 129:315–320.
   PubMed Web of Science ®Google Scholar
• V. Chaar, L. Kéclard, M. Etienne-Julan, J. P. Diara, J. Elion, R. Krishnamoorthy, and M. Romana. (2006). UGT1A1 polymorphism outweighs the modest effect of deletional (-3.7 kb) alpha-thalassemia on cholelithogenesis in sickle cell anemia. Am. J. Hematol. 81:377–379.
   PubMed Web of Science ®Google Scholar
• C. Chen, R. J. Mireles, S. D. Campbell, J. Lin, J. B. Mills, J. J. Xu, and T. A. Smolarek. (2005). Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab. Dispos. 33:537–546.
   PubMed Web of Science ®Google Scholar
• A. Chounta, S. Zouridakis, C. Ellinas, S. Tsiodras, C. Zoumpouli, S. Kopanakis, and H. Giamarellou. (2005). Cholestatic liver injury after glimepiride therapy. J. Hepatol. 42:944–946.
   PubMed Web of Science ®Google Scholar
• J. H. Choi, B. M. Ahn, J. Yi, J. H. Lee, J. H. Lee, S. W. Nam, C. Y. Chon, K. H. Han, S. H. Ahn, I. J. Jang, J. Y. Cho, Y. Suh, M. O. Cho, J. E. Lee, K. H. Kim, and M. G. Lee. (2007). MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet. Genomics. 17:403–415.
   PubMed Web of Science ®Google Scholar
• S. C. Chueh, C. Y. Huang, and M. K. Lai. (2000). Mycophenolate mofetil-induced hyperbilirubinemia in renal transplant recipients. Transplant Proc. 32:1901–1902.
   PubMed Web of Science ®Google Scholar
• J. Y. Chung, J. Y. Cho, K. S. Yu, J. R. Kim, D. S. Oh, H. R. Jung, K. S. Lim, K. H. Moon, S. G. Shin, and I. J. Jang. (2005). Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78:342–350.
   PubMed Web of Science ®Google Scholar
• D. J. Clarke, N. Moghrabi, G. Monaghan, A. Cassidy, M. Boxer, R. Hume, and B. Burchell. (1997). Genetic defects of the UDP-glucuronosyltransferase-1 (UGT1) gene that cause familial non-haemolytic unconjugated hyperbilirubinaemias. Clin. Chem. Acta. 266:63–74.
   PubMed Web of Science ®Google Scholar
• J. F. Côté, S. Kirzin, A. Kramar, J. F. Mosnier, M. D. Diebold, I. Soubeyran, A. S. Thirouard, J. Selves, P. Laurent-Puig, and M. Ychou. (2007). UGT1A1 polymorphism can predict hematologic toxicity in patients treated with irinotecan. Clin. Cancer Res. 13:3269–3275.
   PubMed Web of Science ®Google Scholar
• Y. Cui, J. König, I. Leier, U. Buchholz, and D. Keppler. (2001). Hepatic uptake of bilirubin and its conjugates by the human organic anion transporter SLC21A6. J. Biol. Chem. 276:9626–9630.
   PubMed Web of Science ®Google Scholar
• A. K. Daly, G. P. Aithal, J. B. Leathart, R. A. Swainsbury, T. S. Dang, and C. P. Day. (2007). Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes. Gastroenterology 132:272–281.
   PubMed Web of Science ®Google Scholar
• F. A. de Jong, T. J. Scott-Horton, D. L. Kroetz, H. L. McLeod, L. E. Friberg, R. H. Mathijssen, J. Verweij, S. Marsh, and A. Sparreboom. (2007). Irinotecan-induced diarrhea: functional significance of the polymorphic ABCC2 transporter protein. Clin. Pharmacol. Ther. 81:42–49.
   PubMed Web of Science ®Google Scholar
• P. A. Dennery, D. S. Seidman, and D. K. Stevenson. (2001). Neonatal hyperbilirubinemia. N. Engl. J. Med. 344:581–590.
   PubMed Web of Science ®Google Scholar
• E. Ellis, M. Wagner, F. Lammert, A. Nemeth, J. Gumhold, C. P. Strassburg, C. Kylander, D. Katsika, M. Trauner, C. Einarsson, and H. U. Marschall. (2006). Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. J. Hepatol. 44:243–245.
   PubMed Web of Science ®Google Scholar
• A. A. El-Sheikh, J. J. van den Heuvel, J. B. Koenderink, and F. G. Russel. (2007). Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 320:229–235.
   PubMed Web of Science ®Google Scholar
• W. El-Matary, and M. Dalzell. (2005). Omeprazole-induced hepatitis. Pediatr. Emerg. Care 21:529–530.
   PubMed Web of Science ®Google Scholar
• G. A. Faich, and R. H. Moseley. (2001). Troglitazone (Rezulin) and hepatic injury. Pharmacoepidemiol. Drug Saf. 10:537–547.
   PubMed Web of Science ®Google Scholar
• A. Ferraris, G. D'Amato, V. Nobili, B. Torres, M. Marcellini, and B. Dallapiccola. (2006). Combined test for UGT1A1 -3279T-->G and A(TA)nTAA polymorphisms best predicts Gilbert's syndrome in Italian pediatric patients. Genet. Test 10:121–125.
   PubMedGoogle Scholar
• M. B. Fisher, M. F. Paine, T. J. Strelevitz, and S. A. Wrighton. (2001). The role of hepatic and extrahepatic UDP-glucuronosyltransferases in human drug metabolism. Drug Metab. Rev. 33:273–297.
   PubMed Web of Science ®Google Scholar
• T. Furihata, T. Satoh, N. Yamamoto, K. Kobayashi, and K. Chiba. (2007). Hepatocyte nuclear factor 1 alpha is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm. Res. 24:2327–2332.
   PubMed Web of Science ®Google Scholar
• T. C Goosen, J. N. Bauman, J. A. Davis, C. Yu, S. I. Hurst, J. A. Williams, and C. M. Loi. (2007). Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid. Drug Metab. Dispos. 35:1315–1324.
   PubMed Web of Science ®Google Scholar
• M. A. González de la Puente, E. Calderón, R. Espinosa, M. Rincón, and J. M. Varela. (2001). Fatal hepatotoxicity associated with enalapril. Ann. Pharmacother. 35:1492.
   PubMed Web of Science ®Google Scholar
• B. Gupta, C. LeVea, A. Litwin, and M. G. Fakih. (2007). Reversible grade 4 hyperbilirubinemia in a patient with UGT1A1 7/7 genotype treated with irinotecan and cetuximab. Clin. Colorectal. Cancer 6:447–449.
   PubMed Web of Science ®Google Scholar
• M. Hartleb, A. Nowak, T. Romanczyk, A. Kasicka-Jonderko, and K. Januszewski. (1994). Does hyperthyroidism promote drug hepatotoxicity. Pol. Arch. Med. Wewn. 92:353–356.
   PubMedGoogle Scholar
• M. Hartleb, G. Rymarczyk, and K. Januszewski. (1999). Acute cholestatic hepatitis associated with pravastatin. Am. J. Gastroenterol. 94:1388–1390.
   PubMed Web of Science ®Google Scholar
• M. Hedman, M. Antikainen, C. Holmberg, M. Neuvonen, M. Eichelbaum, K. T. Kivistö, P. J. Neuvonen, and M. Niemi. (2006). Pharmacokinetics and response to pravastatin in paediatric patients with familial hypercholesterolaemia and in paediatric cardiac transplant recipients in relation to polymorphisms of the SLCO1B1 and ABCB1 genes. Br. J. Clin. Pharmacol. 61:706–715.
   PubMed Web of Science ®Google Scholar
• M. Hirano, K. Maeda, Y. Shitara, and Y. Sugiyama. (2004). Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J. Pharmacol. Exp. Ther. 311:139–146.
   PubMed Web of Science ®Google Scholar
• R. H. Ho, L. Choi, W. Lee, G. Mayo, U. I. Schwarz, R.G. Tirona, D. G. Bailey, C. Michael Stein, and R. B. Kim. (2007). Effect of drug transporter genotypes on pravastatin disposition in European- and African-American participants. Pharmacogenet. Genomics. 17:647–656.
   PubMed Web of Science ®Google Scholar
• R. H. Ho, R. G. Tirona, B. F. Leake, H. Glaeser, W. Lee, C. J. Lemke, Y. Wang, and R. B. Kim. (2006). Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130:1793–806.
   PubMed Web of Science ®Google Scholar
• D.J. Hoffman, S.A. Zanelli, J. Kubin, O.P. Mishra, and M. Delivoria-Papadopoulos. (1996). The in vivo effect of bilirubin on the N-methyl-D-aspartate receptor/ion channel complex in the brains of newborn piglets. Pediatr. Res. 40:804–808.
   PubMed Web of Science ®Google Scholar
• T. Höhler, M. Schnütgen, I. Helmreich-Becker, W. J. Mayet, and K. H. Mayer zum Büschenfelde. (1993). Drug-induced hepatitis: a rare complication of oral anticoagulants. J. Hepatol. 21:447–449.
   Web of Science ®Google Scholar
• I. Höllmüller, S. Stadlmann, I. Graziadei, and W. Vogel. (2006). Clinico-histopathological characteristics of clopidogrel-induced hepatic injury: case report and review of literature. Eur. J. Gastroenterol. Hepatol. 18:931–934.
   PubMed Web of Science ®Google Scholar
• B. Hsiang, Y. Zhu, Z. Wang, Y. Wu, V. Sasseville, W. P. Yang, and T. G. Kirchgessner. (1999). A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274:37161–168.
   PubMed Web of Science ®Google Scholar
• T. Y. Hsieh, T. Y. Shiu, S. M. Huang, H. H. Lin, T. C. Lee, P. J. Chen, H. C. Chu, W. K. Chang, K. S. Jeng, M. M. Lai, and Y. C. Chao. (2007). Molecular pathogenesis of Gilbert's syndrome: decreased TATA-binding protein binding affinity of UGT1A1 gene promoter. Pharmacogenet. Genomics. 17:229–236.
   PubMed Web of Science ®Google Scholar
• C. S. Huang, M. J. Huang, M. S. Lin, S. S. Yang, H. C. Teng, and K. S. Tang. (2005). Genetic factors related to unconjugated hyperbilirubinemia amongst adults. Pharmacogenet. Genomics. 15:43–50.
   PubMedGoogle Scholar
• M. J. Huang, K. E. Kua, H. C. Teng, K. S. Tang, H. W. Weng, and C. S. Huang. (2004). Risk factors for severe hyperbilirubinemia in neonates. Pediatr. Res. 56:682–689.
   PubMed Web of Science ®Google Scholar
• K. Hull, R. Horenstein, R. Naglieri, K. Munir, M. Ghany, and F. S. Celi. (2007). Two cases of thyroid storm-associated cholestatic jaundice. Endocr. Pract. 13:476–480.
   PubMedGoogle Scholar
• I. Ieiri, S. Suwannakul, K. Maeda, H. Uchimaru, K. Hashimoto, M. Kimura, H. Fujino, M. Hirano, H. Kusuhara, S. Irie, S. Higuchi, and Y. Sugiyama. (2007). SLCO1B1 (OATP1B1, an uptake transporter) and ABCG2 (BCRP, an efflux transporter) variant alleles and pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 82:541–547.
   PubMed Web of Science ®Google Scholar
• F. Innocenti, W. Liu, P. Chen, A. A. Desai, S. Das, and M. J. Ratain. (2005). Haplotypes of variants in the UDP-glucuronosyltransferase 1A9 and 1A1 genes. Pharmacogenet. Genomics. 15:295–301.
   PubMed Web of Science ®Google Scholar
• A. Iolascon, M. F. Faienza, L. Giordani, S. Perrotta, G. Ruggiu, G. F. Meloni, and E. M. del Giudice. (1999). Bilirubin levels in the acute hemolytic crisis of Glucose-6-phosphate dehydrogenase (G6PD) deficiency are related to Gilbert's syndrome. Eur. J. Haematol. 62:307–310.
   PubMed Web of Science ®Google Scholar
• S. Ito, I. Ieiri, M. Tanabe, A. Suzuki, S. Higuchi, and K. Otubo. (2001). Polymorphism of the ABC transporter genes, MDR1, MRP1 and MRP2/cMOAT, in healthy Japanese subjects. Pharmacogenetics 11:175–184.
   PubMedGoogle Scholar
• M. Itoda, Y. Saito, A. Soyama, M. Saeki, N. Murayama, S. Ishida, K. Sai, M. Nagano, H. Suzuki, Y. Sugiyama, S. Ozawa, and J. Sawada Ji. (2002). Polymorphisms in the ABCC2 (cMOAT/MRP2) gene found in 72 established cell lines derived from Japanese individuals: an association between single nucleotide polymorphisms in the 5’-untranslated region and exon 28. Drug Metab. Dispos. 30:363–364.
   PubMed Web of Science ®Google Scholar
• M. Iwai, H. Suzuki, I. Ieiri, K. Otsubo, and Y. Sugiyama. (2004). Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14:749–757.
   PubMedGoogle Scholar
• S. R. Jada, S. Xiaochen, L. Y. Yan, X. Xiaoqiang, S. Lal, S. F. Zhou, L. L. Ooi, and B. Chowbay. (2007). Pharmacogenetics of SLCO1B1: haplotypes, htSNPs and hepatic expression in three distinct Asian populations. Eur. J. Clin. Pharmacol. 63:555–563.
   PubMed Web of Science ®Google Scholar
• A. Kadakol, S. S. Ghosh, B. S. Sappal, G. Sharma, J. R. Chowdhury, and N. R. Chowdhury. (2000). Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum. Mutat. 16:297–306.
   PubMed Web of Science ®Google Scholar
• S. Kajihara, A. Hisatomi, T. Mizuta, T. Hara, I. Ozaki, I. Wada, and K. Yamamoto. (1998). A splice mutation in the human canalicular multispecific organic anion transporter gene causes Dubin-Johnson syndrome. Biochem. Biophys. Res. Commun. 253:454–457.
   PubMed Web of Science ®Google Scholar
• L. I. Kajosaari, M. Niemi, M. Neuvonen, J. Laitila, P. J. Neuvonen, and J. T. Backman. (2005). Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin. Pharmacol. Ther. 78:388–399.
   PubMed Web of Science ®Google Scholar
• M. Kaplan. (2001). Genetic interactions in the pathogenesis of neonatal hyperbilirubinemia: Gilbert's Syndrome and glucose-6-phosphate dehydrogenase deficiency. J. Perinatol. 21 (Suppl 1):S30–S34.
   PubMedGoogle Scholar
• M. Kaplan, P. Renbaum, H. J. Vreman, R. J. Wong, E. Levy-Lahad, C. Hammerman, and D. K. Stevenson. (2007). (TA)n UGT 1A1 promoter polymorphism: a crucial factor in the pathophysiology of jaundice in G-6-PD deficient neonates. Pediatr. Res. 61:727–731.
   PubMed Web of Science ®Google Scholar
• N. Kaniwa, K. Kurose, H. Jinno, T. Tanaka-Kagawa, Y. Saito, M. Saeki, J. Sawada, M. Tohkin, and R. Hasegawa. (2005). Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C>T (P229L) found in an African-American. Drug Metab. Dispos. 33:458–465.
   PubMed Web of Science ®Google Scholar
• Y. Kato, S. Ikushiro, Y. Emi, S. Tamaki, H. Suzuki, T. Sakaki, S. Yamada, and M. Degawa. (2008). Hepatic UDP-glucuronosyltransferases responsible for glucuronidation of thyroxine in humans. Drug Metab. Dispos. 36:51–55.
   PubMed Web of Science ®Google Scholar
• Y. Kameyama, K. Yamashita, K. Kobayashi, M. Hosokawa, and K. Chiba. (2005). Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics. 15:513–522.
   PubMed Web of Science ®Google Scholar
• D. Keppler, and J. Konig. (2000). Hepatic secretion of conjugated drugs and endogenous substances. Semin. Liver Dis. 20:265–272.
   PubMed Web of Science ®Google Scholar
• C. S. Ki, K. A. Lee, S. Y. Lee, H. J. Kim, S. S. Cho, J. H. Park, S. Cho, K. M. Sohn, and J. W. Kim. (2003). Haplotype structure of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene and its relationship to serum total bilirubin concentration in a male Korean population. Clin. Chem. 49:2078–2081.
   PubMed Web of Science ®Google Scholar
• C. D. King, M. D. Green, G. R. Rios, B. L. Coffman, I. S. Owens, W. P. Bishop, and T. R. Tephly. (1996). The glucuronidation of exogenous and endogenous compounds by stably expressed rat and human UDP-glucuronosyltransferase 1.1. Arch. Biochem. Biophys. 332:92–100.
   PubMed Web of Science ®Google Scholar
• C. Kitagawa, M. Ando, Y. Ando, Y. Sekido, K. Wakai, K. Imaizumi, K. Shimokata, and Y. Hasegawaarua. (2004). Genetic polymorphism in the phenobarbital-responsive enhancer module of the UDP-glucuronosyltransferase 1A1 gene and irinotecan toxicity. Pharmacogenet. Genomics. 15:35–41.
   Google Scholar
• G. E. Kuehl, J. W. Lampe, J. D. Potter, and J. Bigler. (2005). Glucuronidation of nonsteroidal anti-inflammatory drugs: identifying the enzymes responsible in human liver microsomes. Drug Metab. Dispos. 33:1027–1035.
   PubMed Web of Science ®Google Scholar
• C. F. Lacy, L. L. Armstrong, M. P. Goldman, and L. L. Lance. Drug Information Handbook14th. Lexi-Comp, HudsonOH, (2006) .
   Google Scholar
• N. G. Lafuente. (2000). Calcium channel blockers and hepatotoxicity. Am. J. Gastroenterol. 95:2145.
   PubMed Web of Science ®Google Scholar
• S. Lata, and B. Chudy. (2006). Acute cholestatic hepatitis caused by simvastatine in a 67-year-old patient. Przegl. Lek. 63 (Suppl 7):97–98.
   PubMedGoogle Scholar
• A. Loupy, D. Anglicheau, M. F. Mamzer-Bruneel, F. Martinez, E. Thervet, C. Legendre, J. Serpaggi, and S. Pol. (2006). Mycophenolate sodium-induced hepatotoxicity: first report. Transplantation 82:581.
   PubMed Web of Science ®Google Scholar
• R. Mallants, K. Van Oosterwyck, L. Van Vaeck, R. Mols, E. De Clercq, and P. Augustijns. (2005). Multidrug resistance-associated protein 2 (MRP2) affects hepatobiliary elimination but not the intestinal disposition of tenofovir disoproxil fumarate and its metabolites. Xenobiotica. 35:1055–1066.
   PubMed Web of Science ®Google Scholar
• Y. Maruo, C. D'Addario, A. Mori, M. Iwai, H. Takahashi, H. Sato, and Y. Takeuchi. (2004). Two linked polymorphic mutations (A(TA)7TAA and T-3279G) of UGT1A1 as the principal cause of Gilbert syndrome. Hum. Genet. 115:525–526.
   PubMed Web of Science ®Google Scholar
• C. Marzolini, R. G. Tirona, and R. B. Kim. (2004). Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5:273–282.
   PubMed Web of Science ®Google Scholar
• K. Maeda, I. Ieiri, K. Yasuda, A. Fujino, H. Fujiwara, K. Otsubo, M. Hirano, T. Watanabe, Y. Kitamura, H. Kusuhara, and Y. Sugiyama. (2006). Effects of organic anion transporting polypeptide 1B1 haplotype on pharmacokinetics of pravastatin, valsartan, and temocapril. Clin. Pharmacol. Ther. 79:427–439.
   PubMed Web of Science ®Google Scholar
• I. Machida, Y. Inagaki, S. Suzuki, H. Hayashi, and S. Wakusawa. (2004). Mutation analysis of the multidrug resistance protein 2 (MRP2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol. Res. 30:86–90.
   PubMed Web of Science ®Google Scholar
• I. Machida, S. Wakusawa, F. Sanae, H. Hayashi, A. Kusakabe, H. Ninomiya, M. Yano, and K. Yoshioka. (2005). Mutational analysis of the MRP2 gene and long term follow-up of Dubin-Johnson syndrome in Japan. J. Gastroenterol. 40:366–370.
   PubMed Web of Science ®Google Scholar
• R. H. Mathijssen, R. J. van Alphen, J. Verweij, W.J. Loos, K. Nooter, G. Stoter, and A. Sparreboom. (2001). Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin. Cancer Res. 7:2182–2194.
   PubMed Web of Science ®Google Scholar
• O. Meyer, T. Hoffmann, T. Aslan, N. Ahrens, H. Kiesewetter, and A. Salama. (2003). Diclofenac-induced antibodies against RBCs and platelets: two case reports and a concise review. Transfusion. 43:345–349.
   PubMed Web of Science ®Google Scholar
• H. Minami, K. Sai, M. Saeki, Y. Saito, S. Ozawa, K. Suzuki, N. Kaniwa, J. Sawada, T. Hamaguchi, N. Yamamoto, K. Shirao, Y. Yamada, H. Ohmatsu, K. Kubota, T. Yoshida, A. Ohtsu, and N. Saijo. (2007). Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics. 17:497–504.
   PubMed Web of Science ®Google Scholar
• M. Miura, S. Satoh, K. Inoue, H. Kagaya, M. Saito, T. Inoue, T. Suzuki, and T. Habuchi. (2007). Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients. Eur. J. Clin. Pharmacol. 63:1161–1169.
   PubMed Web of Science ®Google Scholar
• R. Mor-Cohen, A. Zivelin, N. Rosenberg, I. Goldberg, and U. Seligsohn. (2005). A novel ancestral splicing mutation in the multidrug resistance protein 2 gene causes Dubin-Johnson syndrome in Ashkenazi Jewish patients. Hepatol. Res. 31:104–111.
   PubMed Web of Science ®Google Scholar
• J. Mwinyi, K. Köpke, M. Schaefer, I. Roots, and T. Gerloff. (2008). Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur. J. Clin. Pharmacol. 64:257–266.
   PubMed Web of Science ®Google Scholar
• R. Mor-Cohen, A. Zivelin, N. Rosenberg, M. Shani, S. Muallem, and U. Seligsohn. (2001). Identification and functional analysis of two novel mutations in the multidrug resistance protein 2 gene in Israeli patients with Dubin-Johnson syndrome. J. Biol. Chem. 276:36923–36930.
   PubMed Web of Science ®Google Scholar
• M. Naesens, D. R. Kuypers, F. Streit, V. W. Armstrong, M. Oellerich, K. Verbeke, and Y. Vanrenterghem. (2006). Rifampin induces alterations in mycophenolic acid glucuronidation and elimination: implications for drug exposure in renal allograft recipients. Clin. Pharmacol. Ther. 80:509–521.
   PubMed Web of Science ®Google Scholar
• T. B. Newman, M. J. Easterling, E. S. Goldman, and D. K. Stevenson. (1990). Laboratory evaluation of jaundice in newborns. Frequency, cost, and yield. Am. J. Dis. Child. 144:364–368.
   PubMedGoogle Scholar
• M. Niemi, K. T. Kivistö, U. Hofmann, M. Schwab, M. Eichelbaum, and M. F. Fromm. (2005a). Fexofenadine pharmacokinetics are associated with a polymorphism of the SLCO1B1 gene (encoding OATP1B1). Br. J. Clin. Pharmacol. 59:602–604.
   PubMed Web of Science ®Google Scholar
• M. Niemi, J. T. Backman, L. I. Kajosaari, J. B. Leathart, M. Neuvonen, A. K. Daly, M. Eichelbaum, K. T. Kivistö, and P. J. Neuvonen. (2005b). Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77:468–478.
   PubMed Web of Science ®Google Scholar
• V. Noronha, B. Burtness, J. Murren, and T. P. Duffy. (2005). Oxaliplatin induces a delayed immune-mediated hemolytic anemia: a case report and review of the literature. Clin. Colorectal Cancer 5:283–286.
   PubMed Web of Science ®Google Scholar
• T. Nozawa, H. Minami, S. Sugiura, A. Tsuji, and I. Tamai. (2005). Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33:434–439.
   PubMed Web of Science ®Google Scholar
• B. Ostanek, D. Furlan, T. Mavec, and J. Lukac-Bajalo. (2007). UGT1A1(TA)n promoter polymorphism--a new case of a (TA)8 allele in Caucasians. Blood Cells Mol. Dis. 38:78–82.
   PubMed Web of Science ®Google Scholar
• J. D. Ostrow, L. Pascolo, D. Brites, and C. Tiribelli. (2004). Molecular basis of bilirubin-induced neurotoxicity. Trends Mol. Med. 10:65–70.
   PubMed Web of Science ®Google Scholar
• M. K. Pasanen, J. T. Backman, P. J. Neuvonen, and M. Niemi. (2006). Frequencies of single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide 1B1 SLCO1B1 gene in a Finnish population. Eur. J. Clin. Pharmacol. 62:409–415.
   PubMed Web of Science ®Google Scholar
• M. K. Pasanen, M. Neuvonen, P. J. Neuvonen, and M. Niemi. (2006). SLCO1B1 polymorphism markedly affects the pharmacokinetics of simvastatin acid. Pharmacogenet. Genomics. 16:873–879.
   PubMed Web of Science ®Google Scholar
• M. K. Pasanen, P. J. Neuvonen, and M. Niemi. (2008). Global analysis of genetic variation in SLCO1B1. Pharmacogenomics 9:19–33.
   PubMed Web of Science ®Google Scholar
• T. M. Pasha, and K. D. Lindor. (1996). Diagnosis and therapy of cholestatic liver disease. Med. Clin. North. Am. 80:995–1019.
   PubMed Web of Science ®Google Scholar
• C. Pauli-Magnus, and P. J. Meier. (2005). Hepatocellular transporters and cholestasis. J. Clin. Gastroenterol. 39:S103–S110.
   PubMed Web of Science ®Google Scholar
• M. Pompili, M. Basso, A. Grieco, F. M. Vecchio, G. Gasbarrini, and G. L. Rapaccini. (2004). Recurrent acute hepatitis associated with use of cetirizine. Ann. Pharmacother. 38:1844–1847.
   PubMed Web of Science ®Google Scholar
• A. Premawardhena, C. A. Fisher, F. Fathiu, S. de Silva, W. Perera, T. E. Peto, N. F. Olivieri, and D. J. Weatherall. (2001). Genetic determinants of jaundice and gallstones in haemoglobin E beta thalassaemia. Lancet 357:1945–1946.
   PubMed Web of Science ®Google Scholar
• A. Premawardhena, C. A. Fisher, Y. T. Liu, I. C. Verma, S. de Silva, M. Arambepola, J. B. Clegg, and D. J. Weatherall. (2003). The global distribution of length polymorphisms of the promoters of the glucuronosyltransferase 1 gene (UGT1A1): hematologic and evolutionary implications. Blood Cells Mol. Dis. 31:98–101.
   PubMed Web of Science ®Google Scholar
• T. Prueksaritanont, J. J. Zhao, B. Ma, B. A. Roadcap, C. Tang, Y. Qiu, L. Liu, J. H. Lin, P. G. Pearson, and T. A. Baillie. (2002). Mechanistic studies on metabolic interactions between gemfibrozil and statins. J. Pharmacol. Exp. Ther. 301:1042–1051.
   PubMed Web of Science ®Google Scholar
• M. T. Raijmakers, P. L. Jansen, E. A. Steegers, and W. H. Peters. (2000). Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J. Hepatol. 33:348–351.
   PubMed Web of Science ®Google Scholar
• T. Rau, B. Erney, R. Göres, T. Eschenhagen, J. Beck, and T. Langer. (2006). High-dose methotrexate in pediatric acute lymphoblastic leukemia: impact of ABCC2 polymorphisms on plasma concentrations. Clin. Pharmacol. Ther. 80:468–476.
   PubMed Web of Science ®Google Scholar
• I. Rigato, M. Cravatari, C. Avellini, E. Ponte, S. L. Crocè, and C. Tiribelli. (2007). Drug induced acute cholestatic liver damage in a patient with mutation of UGT1A1. Nat. Clin. Pract. Gastroenterol. Hepatol. 4:403–408.
   PubMedGoogle Scholar
• J. K. Ritter, F. Chen, Y. Y. Sheen, H. M. Tran, S. Kimura, M. T. Yeatman, and I. S. Owens. (1992). A novel complex locus UGT1 encodes human bilirubin, phenol, and other UDP-glucuronosyltransferase isozymes with identical carboxyl termini. J. Biol. Chem. 267:3257–3261.
   PubMed Web of Science ®Google Scholar
• M. Rotger, P. Taffe, G. Bleiber, H. F. Gunthard, H. Furrer, P. Vernazza, H. Drechsler, E. Bernasconi, M. Rickenbach, A. Telenti, and Swiss HIV Cohort Study. (2005). Gilbert syndrome and the development of antiretroviral therapy-associated hyperbilirubinemia. J. Infect. Dis. 192:1381–1386.
   PubMed Web of Science ®Google Scholar
• S. Russmann, I. Grattagliano, P. Portincasa, V. O. Palmieri, and G. Palasciano. (2006). Ribavirin-induced anemia: mechanisms, risk factors and related targets for future research. Curr. Med. Chem. 13:3351–3357.
   PubMed Web of Science ®Google Scholar
• K. Sackey. (1999). Hemolytic anemia: part 1. Pediatr. Rev. 20:152–158.
   PubMedGoogle Scholar
• M. W. Saif, and P. J. McGee. (2005). Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature. JOP. 6:369–374.
   PubMedGoogle Scholar
• M. Sampietro, and A. Iolascon. (1999). Molecular pathology of Crigler-Najjar type I and II and Gilbert's syndromes. Haematologica. 84:150–157.
   PubMed Web of Science ®Google Scholar
• A. Seltsam, and A. Salama. (2000). Ceftriaxone-induced immune haemolysis: two case reports and a concise review of the literature. Intensive Care Med. 26:1390–1394.
   PubMed Web of Science ®Google Scholar
• S. B. Senafi, D. J. Clarke, and B. Burchell. (1994). Investigation of the substrate specificity of a cloned expressed human bilirubin UDP-glucuronosyltransferase: UDP-sugar specificity and involvement in steroid and xenobiotic glucuronidation. Biochem. J. 303:233–240.
   PubMed Web of Science ®Google Scholar
• S. Sherlock, and J. Dooley. Disease of the liver and biliary system11th. Blackwell Science, MaldenMA, (2002) .
   Google Scholar
• Y. Shitara, D. Sugiyama, H. Kusuhara, Y. Kato, T. Abe, P. J. Meier, T. Itoh, and Y. Sugiyama. (2002). Comparative inhibitory effects of different compounds on rat oatpl (slc21a1) and Oatp2 (Slc21a5)-mediated transport. Pharm. Res. 19:147–153.
   PubMed Web of Science ®Google Scholar
• J. Shoda, H. Suzuki, H. Suzuki, Y. Sugiyama, M. Hirouchi, H. Utsunomiya, K. Oda, T. Kawamoto, Y. Matsuzaki, and N. Tanaka. (2003). Novel mutations identified in the human multidrug resistance-associated protein 2 (MRP2/ABCC2) gene in a Japanese patient with Dubin-Johnson syndrome. Hepatol. Res. 27:323–326.
   PubMedGoogle Scholar
• J. Sugatani, H. Kojima, A. Ueda, S. Kakizaki, K. Yoshinari, Q. H. Gong, and et al (2001). The phenobarbital resoponse enhancer module in the human bilirubin UDP-glucuronosyltransferase UGT1A1 gene and regulation by the nuclear receptor CAR. Hepatology 33:1232–1238.
   PubMed Web of Science ®Google Scholar
• H. Suzuki, and Y. Sugiyama. (2002). Single nucleotide polymorphisms in multidrug resistance associated protein 2 (MRP2/ABCC2): its impact on drug disposition. Adv. Drug Deliv. Rev. 54:1311–1331.
   PubMed Web of Science ®Google Scholar
• H. Takane, M. Miyata, N. Burioka, J. Kurai, Y. Fukuoka, H. Suyama, Y. Shigeoka, K. Otsubo, I. Ieiri, and E. Shimizu. (2007). Severe toxicities after irinotecan-based chemotherapy in a patient with lung cancer: a homozygote for the SLCO1B1*15 allele. Ther. Drug Monit. 29:666–668.
   PubMed Web of Science ®Google Scholar
• K. Takeuchi, Y. Kobayashi, S. Tamaki, T. Ishihara, Y. Maruo, J. Araki, R. Mifuji, T. Itani, M. Kuroda, H. Sato, M. Kaito, and Y. Adachi. (2004). Genetic polymorphisms of bilirubin uridine diphosphate-glucuronosyltransferase gene in Japanese patients with Crigler-Najjar syndrome or Gilbert's syndrome as well as in healthy Japanese subjects. J. Gastroenterol. Hepatol. 19:1023–1028.
   PubMed Web of Science ®Google Scholar
• P. D. Thompson, P. Clarkson, and R. H. Karas. (2003). Statin-associated myopathy. JAMA. 289:1681–1690.
   PubMed Web of Science ®Google Scholar
• L. M. TierneyJr., S. J. McPhee, and M. A. Papadakis. Current Medical Diagnosis & Treatment45th. The McGraw-Hill Companies, New York, (2006) .
   Google Scholar
• S. Toh, M. Wada, T. Uchiumi, A. Inokuchi, Y. Makino, Y. Horie, Y. Adachi, S. Sakisaka, and M. Kuwano. (1999). Genomic structure of the canalicular multispecific organic anion-transporter gene (MRP2/cMOAT) and mutations in the ATP-binding-cassette region in Dubin-Johnson syndrome. Am. J. Hum. Genet. 64:739–746.
   PubMed Web of Science ®Google Scholar
• F. Topal, E. Ozaslan, S. Akbulut, M. Küçükazman, O. Yüksel, and E. Altiparmak. (2006). Methylprednisolone-induced toxic hepatitis. Ann. Pharmacother. 40:1868–1871.
   PubMed Web of Science ®Google Scholar
• B. Y. Tung, and R. L. CarithersJr.. (1999). Cholestasis and alcoholic liver disease. Clin. Liver Dis. 3:585–601.
   PubMedGoogle Scholar
• W. Udomuksorn, D. J. Elliot, B. C. Lewis, P. I. Mackenzie, K. Yoovathaworn, and J. O. Miners. (2007). Influence of mutations associated with Gilbert and Crigler-Najjar type II syndromes on the glucuronidation kinetics of bilirubin and other UDP-glucuronosyltransferase 1A substrates. Pharmacogenet. Genomics. 17:1017–1029.
   PubMed Web of Science ®Google Scholar
• M. Varriale, A. Salvio, F. Giannattasio, T. d'Errico, L. Montone, F. Borgia, I. Gentile, L. Reynaud, G. Borgia, R. Rossiello, and M. Visconti. (2004). Intrahepatic cholestatic jaundice related to administration of ranitidine. A case report with histologic and ultramicroscopic study. Minerva. Gastroenterol. Dietol. 50:339–343.
   PubMedGoogle Scholar
• M. Wada, S. Toh, K. Taniguchi, T. Nakamura, T. Uchiumi, K. Kohno, I. Yoshida, A. Kimura, S. Sakisaka, Y. Adachi, and M. Kuwano. (1998). Mutations in the canilicular multispecific organic anion transporter (cMOAT) gene, a novel ABC transporter, in patients with hyperbilirubinemia II/Dubin-Johnson syndrome. Hum. Mol. Genet. 7:203–207.
   PubMed Web of Science ®Google Scholar
• S. Wakusawa, I. Machida, S. Suzuki, H. Hayashi, M. Yano, and K. Yoshioka. (2003). Identification of a novel 2026G-->C mutation of the MRP2 gene in a Japanese patient with Dubin-Johnson syndrome. J. Hum. Genet. 48:425–429.
   PubMed Web of Science ®Google Scholar
• J. Weiss, D. Theile, N. Ketabi-Kiyanvash, H. Lindenmaier, and W. E. Haefeli. (2007). Inhibition of MRP1/ABCC1, MRP2/ABCC2, and MRP3/ABCC3 by nucleoside, nucleotide, and non-nucleoside reverse transcriptase inhibitors. Drug Metab. Dispos. 35 (3):340–344.
   PubMed Web of Science ®Google Scholar
• H. J. Willens. (2000). Clopidogrel-induced mixed hepatocellular and cholestatic liver injury. Am. J. Ther. 7:317–318.
   PubMedGoogle Scholar
• M. S. Wright. (1999). Drug induced hemolytic anemias: Increasing complications to therapeutic interventions. Clin. Lab. Sci. 12:115–118.
   PubMedGoogle Scholar
• C. Xu, C. Y. Li, and A. N. Kong. (2005). Induction of phase I, II, and III drug metabolism/transport by xenobiotics. Arch. Pharm. Res. 28:249–268.
   PubMed Web of Science ®Google Scholar
• L. Y. Xu, Y. J. He, W. Zhang, S. Deng, Q. Li, W. X. Zhang, Z. Q. Liu, D. Wang, Y. F. Huang, H. H. Zhou, and Z. Q. Sun. (2007). Organic anion transporting polypeptide-1B1 haplotypes in Chinese patients. Acta. Pharmacol. Sin. 28:1693–1697.
   PubMed Web of Science ®Google Scholar
• W. W. Yew, and C. C. Leung. (2006). Antituberculosis drugs and hepatotoxicity. Respirology 11:699–707.
   PubMed Web of Science ®Google Scholar
• H. Yokoyama, T. Horie, and S. Awazu. (2005). Naproxen-induced oxidative stress in the isolated perfused rat liver. Chem. Biol. Interact. 160:150–158.
   Web of Science ®Google Scholar
• W. P. Yong, J. Ramirez, F. Innocenti, and M. J. Ratain. (2005). Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes. Clin. Cancer Res. 11:6699–6704.
   PubMed Web of Science ®Google Scholar
• M. W. Yu, K. J. Hsiao, K. D. Wuu, and C. J. Chen. (1992). Association between glucose-6-phosphate dehydrogenase deficiency and neonatal jaundice: interaction with multiple risk factors. Am. J. Hematol. 51:19–25.
   Google Scholar
• W. Zhang, Y. J. He, C. T. Han, Z. Q. Liu, Q. Li, L. Fan, Z. R. Tan, W. X. Zhang, B. N. Yu, D. Wang, D. L. Hu, and H. H. Zhou. (2006). Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol. 62:567–572.
   PubMed Web of Science ®Google Scholar
• W. Zhang, Y. J. He, Z. Gan, L. Fan, Q. Li, A. Wang, Z. Q. Liu, S. Deng, Y. F. Huang, L. Y. Xu, and H. H. Zhou. (2007). OATP1B1 polymorphism is a major determinant of serum bilirubin level but not associated with rifampicin-mediated bilirubin elevation. Clin. Exp. Pharmacol. Physiol. 34:1240–1244.
   PubMed Web of Science ®Google Scholar
• W. Zhang, B. L. Chen, V. Ozdemir, Y. J. He, G. Zhou, D. D. Peng, S. Deng, Q. Y. Xie, W. Xie, L. Y. Xu, L. C. Wang, L. Fan, A. Wang, and H. H. Zhou. (2007). SLCO1B1 521T-->C functional genetic polymorphism and lipid-lowering efficacy of multiple-dose pravastatin in Chinese coronary heart disease patients. Br. J. Clin. Pharmacol. 64:346–352.
   PubMed Web of Science ®Google Scholar
• A. Zielinska, C. F. Lichti, S. Bratton, N. C. Mitchell, A. Gallus-Zawada, V. H. Le, M. Finel, G. P. Miller, A. Radominska-Pandya, and J. H. Moran. (2008). Glucuronidation of monohydroxylated warfarin metabolites by human liver microsomes and human recombinant UDP-glucuronosyltransferases. J. Pharmacol. Exp. Ther. 324:139–48.
   PubMed Web of Science ®Google Scholar